BioAge Labs Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-75.79	-71.11	-63.85	-39.72
Depreciation & Amortization	0.19	0.17	0.16	0.13
Loss (Gain) From Sale of Assets	0.06	0.06	-	-
Stock-Based Compensation	11.69	6.98	3.02	2.54
Other Operating Activities	-0.15	1.21	16.6	0.08
Change in Accounts Payable	2.97	0.01	-0.39	0.99
Change in Unearned Revenue	8.06	9.19	3.31	-
Change in Other Net Operating Assets	-5.03	1.98	3.79	-0.2
Operating Cash Flow	-58.51	-51.52	-37.36	-36.18
Capital Expenditures	-0.63	-0.37	-0.17	-0.1
Investment in Securities	-80.18	-	-0.1	-
Investing Cash Flow	-80.81	-0.37	-0.27	-0.1
Short-Term Debt Issued	-	-	23.5	-
Long-Term Debt Issued	-	-	12.5	2.5
Total Debt Issued	-	-	36	2.5
Long-Term Debt Repaid	-	-6	-1	-
Net Debt Issued (Repaid)	-6	-6	35	2.5
Issuance of Common Stock	27.65	222.25	0	0.04
Other Financing Activities	-1.29	-5.05	-0.06	-0.05
Financing Cash Flow	20.36	381.2	34.94	2.5
Foreign Exchange Rate Adjustments	0.07	0.08	-	0.25
Net Cash Flow	-118.9	329.39	-2.69	-33.54
Free Cash Flow	-59.15	-51.89	-37.53	-36.28
Free Cash Flow Per Share	-1.65	-4.84	-22.43	-21.70
Cash Interest Paid	0.8	1.42	1.16	0.13
Levered Free Cash Flow	-41.48	-34.21	-27.91	-
Unlevered Free Cash Flow	-40.9	-32.73	-23.04	-
Change in Working Capital	5.49	11.18	6.71	0.8

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q